

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ALLIA 143A	APPLICATION NO. 08/779,767
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Habib Zaghouni	
		FILING DATE 01/07/97	GROUP 1644

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
PN	A	Liu, C et al. (1996) FcγRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopes. J. Clin. Invest. 98(9) 2001-2007
PN	B	Min, B et al. (1998) Neonatal exposure to a self-peptide-immunoglobulin chimera circumvents the use of adjuvant and confers resistance to autoimmune disease by a novel mechanism involving interleukin 4 lymph node deviation and interferon γ-mediated splenic anergy. J. Exp. Med. 188(11) 2007-2017
PN	C	Legge, et al. (1997) Presentation of a T-cell receptor antagonist peptide by immunoglobulins ablates activation of T cells by a synthetic peptide or protein requiring endocytic processing. J. Exp. Med. 185(6) 1043-1053
	D	(03/08/00) PCT International Search Report in 6 pages. Courtesy Copy

S:\DOCS\DOH\DOH-4503.DOC

EXAMINER	<i>Peterson / NDR</i>	DATE CONSIDERED	<i>3-20-01</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT			